Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis

Arthritis and Rheumatology

Volumn 68, Issue 7, 2016, Pages 1738-1750

  Munters, Li Alemo ^a   Loell, Ingela ^b   Ossipova, Elena ^b   Raouf, Joan ^b   Dastmalchi, Maryam ^b   Lindroos, Eva ^b   Chen, Yi Wen ^c   Esbjörnsson, Mona ^b   Korotkova, Marina ^b   Alexanderson, Helene ^b   Nagaraju, Kanneboyina ^c   Crofford, Leslie J ^a   Jakobsson, Per Johan ^b   Lundberg, Ingrid E ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA6 INTEGRIN; CALNEXIN; CD40 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR7; EMERIN; FLT3 LIGAND; HISTONE DEACETYLASE 5; INITIATION FACTOR 4E; INSULIN RECEPTOR; JUNCTIONAL ADHESION MOLECULE B; LACTIC ACID; LECTIN MANNOSE BINDING 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MANNOSE BINDING LECTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 5; MYOSIN I; MYOSIN IB; MYOSIN VIIA; PEPTIDES AND PROTEINS; PROGRAMMED DEATH 1 LIGAND 1; RIBOSOMAL PROTEIN L27; RIBOSOMAL PROTEIN S8; RIBOSOME PROTEIN; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TENSIN; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

AEROBIC METABOLISM; ARTICLE; CAPILLARY DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLING; CYTOSKELETON; DERMATOMYOSITIS; DISEASE ACTIVITY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; ENDURANCE TRAINING; EXHAUSTION; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MASS SPECTROMETRY; MITOCHONDRIAL BIOGENESIS; MOLECULAR BIOLOGY; MUSCLE BIOPSY; MUSCLE CAPILLARY; MUSCLE GROWTH; MUSCLE HYPERTROPHY; OXIDATIVE PHOSPHORYLATION; PILOT STUDY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEOMICS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKELETAL MUSCLE; UPREGULATION;

EID: 84976583171     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39624     Document Type: Article

References (53)

1. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 2009;48:134–9.
2. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 2009;10:1183–90.
3. Rayavarapu S, Coley W, Kinder TB, Nagaraju K. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle 2013;3:13.
4. Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012;24:201–7.
5. Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012;71 Suppl 2:i82–5.
6. Henriques-Pons A, Nagaraju K. Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol 2009;21:581–7.
7. Rayavarapu S, Coley W, Nagaraju K. An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol 2011;23:579–84.
8. Rayavarapu S, Coley W, Nagaraju K. Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr Rheumatol Rep 2012;14:238–43.
9. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011;7:297–306.
10. Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres: early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997;120:39–45.
11. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep 2001;3:334–45.
12. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009;278:25–9.
13. Varadhachary AS, Weihl CC, Pestronk A. Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol 2010;22:651–7.
14. Dastmalchi M, Alexanderson H, Loell I, Stahlberg M, Borg K, Lundberg IE, et al. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 2007;57:1303–10.
15. Loell I, Helmers SB, Dastmalchi M, Alexanderson H, Munters LA, Nennesmo I, et al. Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies: evident in chronic but not in untreated newly diagnosed patients. Clin Physiol Funct Imaging 2011;31:18–25.
16. Cea G, Bendahan D, Manners D, Hilton-Jones D, Lodi R, Styles P, et al. Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study. Brain 2002;125:1635–45.
17. Grundtman C, Tham E, Ulfgren AK, Lundberg IE. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008;58:3224–38.
18. Alemo Munters L, Alexanderson H, Crofford LJ, Lundberg IE. New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep 2014;16:429.
19. Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol 2009;21:599–603.
20. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol Respir Environ Exerc Physiol 1984;56:831–8.
21. Alemo Munters L, Dastmalchi M, Katz A, Esbjornsson M, Loell I, Hanna B, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther 2013;15:R83.
22. Alemo Munters L, Dastmalchi M, Andgren V, Emilson C, Bergegard J, Regardt M, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken) 2013;65:1959–68.
23. Egan B, Dowling P, O'Connor PL, Henry M, Meleady P, Zierath JR, et al. 2-D DIGE analysis of the mitochondrial proteome from human skeletal muscle reveals time course-dependent remodelling in response to 14 consecutive days of endurance exercise training. Proteomics 2011;11:1413–28.
24. Holloway KV, O'Gorman M, Woods P, Morton JP, Evans L, Cable NT, et al. Proteomic investigation of changes in human vastus lateralis muscle in response to interval-exercise training. Proteomics 2009;9:5155–74.
25. Malm C, Yu JG. Exercise-induced muscle damage and inflammation: re-evaluation by proteomics. Histochem Cell Biol 2012;138:89–99.
26. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403–7.
27. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
28. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40:1262–73.
29. Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the Myositis Disease Activity Assessment Tool. Arthritis Rheum 2008;58:3593–9.
30. Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy: a useful diagnostic and assessment tool. J Rheumatol 2001;28:1591–9.
31. Chen YW, Zhao P, Borup R, Hoffman EP. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 2000;151:1321–36.
32. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods 2009;6:359–62.
33. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33–43.
34. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:654–61.
35. Zoladz JA, Semik D, Zawadowska B, Majerczak J, Karasinski J, Kolodziejski L, et al. Capillary density and capillary-to-fibre ratio in vastus lateralis muscle of untrained and trained men. Folia Histochem Cytobiol 2005;43:11–7.
36. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281–90.
37. Rayavarapu S, Coley W, van der Meulen JH, Cakir E, Tappeta K, Kinder TB, et al. Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target. Arthritis Rheum 2013;65:3248–58.
38. Rayavarapu S, Coley W, Kinder TB, Nagaraju K. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle 2013;3:13.
39. Coffey VG, Hawley JA. The molecular bases of training adaptation. Sports Med 2007;37:737–63.
40. Irrcher I, Adhihetty PJ, Joseph AM, Ljubicic V, Hood DA. Regulation of mitochondrial biogenesis in muscle by endurance exercise. Sports Med 2003;33:783–93.
41. Coggan AR, Spina RJ, King DS, Rogers MA, Brown M, Nemeth PM, et al. Skeletal muscle adaptations to endurance training in 60- to 70-yr-old men and women. J Appl Physiol (1985) 1992;72:1780–6.
42. + cells. Blood 1997;90:3903–13.
43. Solanilla A, Grosset C, Lemercier C, Dupouy M, Mahon FX, Schweitzer K, et al. Expression of Flt3-ligand by the endothelial cell. Leukemia 2000;14:153–62.
44. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 2012;11:649–59.
45. Hoier B, Nordsborg N, Andersen S, Jensen L, Nybo L, Bangsbo J, et al. Pro- and anti-angiogenic factors in human skeletal muscle in response to acute exercise and training. J Physiol 2012;590:595–606.
46. McCarthy JJ, Esser KA. Skeletal muscle adaptation to exercise. In: Hill JA, Olson EN, editors. Muscle: fundamental biology and mechanisms of disease. Vol. 2. Waltham (MA): Elsevier/Academic Press; 2012. p. 911–20.
47. Sparling DP, Griesel BA, Weems J, Olson AL. GLUT4 enhancer factor (GEF) interacts with MEF2A and HDAC5 to regulate the GLUT4 promoter in adipocytes. J Biol Chem 2008;283:7429–37.
48. Frost RA, Lang CH. Regulation of insulin-like growth factor-I in skeletal muscle and muscle cells. Minerva Endocrinol 2003;28:53–73.
49. Deldicque L, Hespel P, Francaux M. Endoplasmic reticulum stress in skeletal muscle: origin and metabolic consequences. Exerc Sport Sci Rev 2012;40:43–9.
50. Xiaoyu D, Yunxia W, Qi F, Dapeng W, Xiuying C, Jianhua J, et al. Expression of B7-homolog 1 in polymyositis. Ann Clin Lab Sci 2011;41:154–60.
51. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 2000;164:6593–600.
52. Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003;42:861–8.
53. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. Resistance exercise decreases skeletal muscle tumor necrosis factor α in frail elderly humans. FASEB J 2001;15:475–82.